Abstract: Formulations for treating proliferative disorders have been developed. In some forms, the formulations are in the form of an injectable aqueous solution for treating tumors and contain exatecan mesylate, optionally including an immunostimulatory agent or adjuvant such as an immunostimulatory oligonucleotide (CpG), at a pH at which the exatecan is soluble until the pH is raised by contacting normal tissue. In some forms, the formulations contain core-shell particles, containing an exatecan in its free base form, a hydrophobic core, and a shell, coating, or corona containing hyperbranched polyglycerol in which hydroxyl groups of the hyperbranched polyglycerol are converted to aldehydes, to adhere the particles to tissue.

Abstract: Described herein are methods and compositions useful to reduce (partially/inhibit or completely—prevent) skin cancer development in an individual in need thereof.

Abstract: Described herein are methods and compositions useful to reduce (partially/inhibit or completely—prevent) skin cancer development in an individual in need thereof.

Abstract: Described herein are methods and compositions useful to reduce (partially/inhibit or completely—prevent) skin cancer development in an individual in need thereof.

Abstract: Described herein are probes useful to detect gene copy number alterations of genes characteristic/indicative of cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement, including probes specific to genes amplified or deleted in cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement; methods of detecting a (one or more) genetic abnormality, such as one or more gene copy number alteration (GCNA), characteristic/indicative of cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement, in a biological sample obtained from an individual; and methods of determining if an individual has cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement, or is likely to develop cutaneous T cell lymphoma (CTCL) with blood involvement.

Abstract: Infused liquid beverages are made from infusion bags (for example tea bags) having a string and tag attached in a container comprising a receptacle for holding the infusing liquid, a lid for the receptacle provided with an opening having a first portion which is capable of gripping the string of the infusion bag and a second portion through which the string of the infusion bag can move into and out of the container.